 The United States Department of Justice fined GlaxoSmithKline $3 billion in 2012, for withholding data, unlawfully promoting use in those under 18, and preparing an article that misleadingly reported the effects of paroxetine in adolescents with depression following its clinical trial study 329.In early 2004, GSK agreed to settle charges of consumer fraud for $2.5 million.The legal discovery process also uncovered evidence of deliberate, systematic suppression of unfavorable Paxil research results.